Home » Stocks » AGEN

Agenus Inc. (AGEN)

Stock Price: $3.01 USD -0.06 (-1.95%)
Updated May 10, 2021 4:00 PM EDT - Market closed
After-hours: $2.97 -0.04 (-1.33%) May 10, 5:12 PM
Market Cap 682.89M
Revenue (ttm) 84.76M
Net Income (ttm) -190.13M
Shares Out 200.33M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $3.01
Previous Close $3.07
Change ($) -0.06
Change (%) -1.95%
Day's Open 3.05
Day's Range 2.99 - 3.12
Day's Volume 2,071,836
52-Week Range 2.28 - 5.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The company announced mixed Q1 results on a day when many biotech stocks were sinking.

4 days ago - The Motley Fool

Agenus (AGEN) delivered earnings and revenue surprises of 12.90% and -46.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines des...

4 days ago - GlobeNewsWire

LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design...

1 week ago - GlobeNewsWire

Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET

2 weeks ago - GlobeNewsWire

LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adj...

3 weeks ago - GlobeNewsWire

LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d...

3 weeks ago - GlobeNewsWire

LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design...

1 month ago - GlobeNewsWire

Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Agenus (NASDAQ:AGEN) moved higher by 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 9.09% year over year to ($0.20), which beat ...

1 month ago - Benzinga

LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines ...

1 month ago - GlobeNewsWire

LEXINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d...

1 month ago - GlobeNewsWire

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

3 months ago - GlobeNewsWire

Agenus Inc (NASDAQ: AGEN) has announced positive preliminary results from its Phase 1 trial evaluating its iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidia...

3 months ago - Benzinga

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

3 months ago - GlobeNewsWire

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

3 months ago - GlobeNewsWire

Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

Agenus is nearing multiple upward inflection points. iNKT therapy trial started, showing immunotherapy leadership.

5 months ago - Seeking Alpha

LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

6 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d...

6 months ago - GlobeNewsWire

An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.

6 months ago - The Motley Fool

LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infect...

6 months ago - GlobeNewsWire

Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Agenus (AGEN) delivered earnings and revenue surprises of -7.69% and 5.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...

6 months ago - GlobeNewsWire

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am

6 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines desi...

6 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines desi...

6 months ago - GlobeNewsWire

Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results

Other stocks mentioned: SGEN
7 months ago - Seeking Alpha

MK-4830 Phase 1 early results are positive.

7 months ago - Seeking Alpha

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

7 months ago - Zacks Investment Research

LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines d...

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines d...

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines d...

7 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines d...

7 months ago - GlobeNewsWire

Investor optimism is increasing ahead of an oral presentation at ESMO 2020.

8 months ago - The Motley Fool

LEXINGTON, Mass., Aug. 26, 2020 /PRNewswire/ -- Agenus Inc.

8 months ago - PRNewsWire

Agenus: Serial Underperformer's Deep I-O Pipeline Approaching Key Inflection Points

8 months ago - Seeking Alpha

Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Agenus Approaches Stock-Propelling Events

8 months ago - Seeking Alpha

Agenus Inc. (AGEN) CEO Garo Armen on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

About AGEN

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company als... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2000
CEO
Garo Armen
Employees
359
Stock Exchange
NASDAQ
Ticker Symbol
AGEN
Full Company Profile

Financial Performance

In 2020, Agenus's revenue was $88.17 million, a decrease of -41.24% compared to the previous year's $150.05 million. Losses were -$180.91 million, 68.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Agenus stock is "Strong Buy." The 12-month stock price forecast is 7.50, which is an increase of 149.17% from the latest price.

Price Target
$7.50
(149.17% upside)
Analyst Consensus: Strong Buy